114 related articles for article (PubMed ID: 23367753)
1. [Age-related macular degeneration and glaucoma: intraocular pressure monitoring after intravitreal injections].
Avetisov SE; Erichev VP; Budzinskaia MV; Karpilova MA; Gurova IV; Shchegoleva IV; Chikun EA
Vestn Oftalmol; 2012; 128(6):3-5. PubMed ID: 23367753
[TBL] [Abstract][Full Text] [Related]
2. [Evaluating the efficacy of anti-VEGF therapy in patients with exudative age-related macular degeneration and concomitant glaucoma].
Erichev VP; Budzinskaya MV; Karpilova MA; Yulova AG; Smirnova TV; Andreeva IV; Shchegoleva IV; Plyukhova AA
Vestn Oftalmol; 2015; 131(3):27-33. PubMed ID: 26310004
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
[TBL] [Abstract][Full Text] [Related]
4. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.
Good TJ; Kimura AE; Mandava N; Kahook MY
Br J Ophthalmol; 2011 Aug; 95(8):1111-4. PubMed ID: 20702430
[TBL] [Abstract][Full Text] [Related]
5. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab.
Martinez-de-la-Casa JM; Ruiz-Calvo A; Saenz-Frances F; Reche-Frutos J; Calvo-Gonzalez C; Donate-Lopez J; Garcia-Feijoo J
Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6214-8. PubMed ID: 22915037
[TBL] [Abstract][Full Text] [Related]
6. [Intraocular pressure and ocular blood flow features intravitreal infection of anti-vascular endothelial growth factor agents].
Mamikonian VR; Galoian NS; Budzinskaia MV; Kazarian ÉÉ; Sdobnikova SV; Shmeleva-Demir OA; Rafaeian AA; Ryzhkova EG
Vestn Oftalmol; 2014; 130(5):16-21. PubMed ID: 25711057
[TBL] [Abstract][Full Text] [Related]
7. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.
Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ
Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465
[TBL] [Abstract][Full Text] [Related]
8. Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration.
Pushpoth S; Sykakis E; Merchant K; Browning AC; Gupta R; Talks SJ
Br J Ophthalmol; 2012 Dec; 96(12):1469-73. PubMed ID: 23001255
[TBL] [Abstract][Full Text] [Related]
9. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
Heier JS; Antoszyk AN; Pavan PR; Leff SR; Rosenfeld PJ; Ciulla TA; Dreyer RF; Gentile RC; Sy JP; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):633.e1-4. PubMed ID: 16483659
[TBL] [Abstract][Full Text] [Related]
10. Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry.
Fuest M; Kotliar K; Walter P; Plange N
Ophthalmic Physiol Opt; 2014 Jul; 34(4):438-44. PubMed ID: 24731161
[TBL] [Abstract][Full Text] [Related]
11. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections.
Skalicky SE; Ho I; Agar A; Bank A
Ophthalmic Surg Lasers Imaging; 2012 Jul; 43(4):328-34. PubMed ID: 22788585
[TBL] [Abstract][Full Text] [Related]
12. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Rosenfeld PJ; Heier JS; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
[TBL] [Abstract][Full Text] [Related]
13. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections.
Arias L; Roman I; Masuet-Aumatell C; Rubio MJ; Caminal JM; Catala J; Pujol O
Retina; 2011; 31(7):1261-7. PubMed ID: 21499194
[TBL] [Abstract][Full Text] [Related]
14. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab.
Parravano M; Oddone F; Tedeschi M; Schiano Lomoriello D; Chiaravalloti A; Ripandelli G; Varano M
Retina; 2009 Mar; 29(3):329-34. PubMed ID: 19092732
[TBL] [Abstract][Full Text] [Related]
15. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab.
Segal O; Ferencz JR; Cohen P; Nemet AY; Nesher R
Isr Med Assoc J; 2013 Jul; 15(7):352-5. PubMed ID: 23943979
[TBL] [Abstract][Full Text] [Related]
16. Retinal blood flow in response to an intravitreal injection of ranibizumab for neovascular age-related macular degeneration.
Micieli JA; Tsui E; Lam WC; Brent MH; Devenyi RG; Hudson C
Acta Ophthalmol; 2012 Feb; 90(1):e13-20. PubMed ID: 21801339
[TBL] [Abstract][Full Text] [Related]
17. Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure.
Goktas A; Goktas S; Atas M; Demircan S; Yurtsever Y
Cutan Ocul Toxicol; 2013 Mar; 32(1):23-6. PubMed ID: 22737998
[TBL] [Abstract][Full Text] [Related]
18. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
[TBL] [Abstract][Full Text] [Related]
19. Intraocular pressure changes related to intravitreal injections of ranibizumab: analysis of pseudophakia and glaucoma subgroup.
Demirel S; Yanik O; Batioglu F; Ozmert E
Int Ophthalmol; 2015 Aug; 35(4):541-7. PubMed ID: 25079762
[TBL] [Abstract][Full Text] [Related]
20. The ocular pulse amplitude at different intraocular pressure: a prospective study.
Knecht PB; Bosch MM; Michels S; Mannhardt S; Schmid U; Bosch MA; Menke MN
Acta Ophthalmol; 2011 Aug; 89(5):e466-71. PubMed ID: 21401909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
